William Blair & Company
CABA icon

William Blair & Company’s Cabaletta Bio CABA Stock Holding History

William Blair & Company’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,650
Closed -$94.6K – 1833
2024
Q2 		$94.6K Sell
12,650
-14,650
-54% -$180K ﹤0.01% 1517
2024
Q1 		$466K Buy
27,300
+8,762
+47% +$188K ﹤0.01% 1102
2023
Q4 		$421K Buy
+18,538
New +$312K ﹤0.01% 1119

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

William Blair & Company's CABA Position: Q3 2024 in Review

William Blair & Company sold out of Cabaletta Bio (CABA) in Q3 2024, closing a stake of 12,650 shares — an estimated $94.6K sold.

William Blair & Company first reported a position in CABA in Q4 2023 and held it in 3 quarters. The position peaked at $466K in Q1 2024. 120 funds tracked by Wall St. Rank hold CABA as of Q3 2024.

  • William Blair & Company reported no remaining Cabaletta Bio position as of Q3 2024 after selling out during the quarter.
  • William Blair & Company sold 12,650 Cabaletta Bio shares in Q3 2024, an estimated $94.6K.
  • William Blair & Company first reported a position in Cabaletta Bio in Q4 2023 and held it in 3 quarters.
  • William Blair & Company's Cabaletta Bio position peaked at $466K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2024.

Based on William Blair & Company's 13F filing for Q3 2024, filed 12 Nov 2024.